Media Invitation - Montreal-based Esperas Pharma Inc. to announce an important investment in a new anti-cancer treatment entering clinical trials

In collaboration with Q-CROC, the trial will be held at several major Montreal hospitals

MONTREAL, April 7, 2016 /CNW Telbec/ - In presence of Mr. Denis Coderre, Mayor of Montreal, Caroline Fortier, CEO of Esperas Pharma, Gaétan Morin, President and CEO of the Fonds de solidarité FTQ, and Luc Marengere, Managing Partner, of TVM Capital invite members of the media to attend a press conference announcing the start of the first-in-man clinical trial of ESP-01, an oral anti-cancer agent. The trial for this promising new treatment option will be run by Esperas Pharma Inc. in partnership with the Quebec Clinical Research Organization in Cancer (Q-CROC).

WHEN:		April 11, 2016 9:00 a.m.: Beginning of news conference and speeches  9:30 a.m.: Individual interviews and photo opportunities
WHO:		The Honourable Denis Coderre, Mayor of Montreal Gaétan Morin, President and CEO, Fonds de solidarité FTQ Dr. Fabrice Brunet, President and Chief Executive Officer, CHUM and CHU Sainte-Justine Luc Marengere, Managing Partner, TVM Capital Dr. Gerald Batist, Scientific Director, Q-CROC, and Dr. Fred Saad, Director of clinical research in uro-oncology and Chair of the Board, Q-CROC Caroline Fortier, CEO, Esperas Pharma Inc.
WHERE:		Centre de recherche du CHUM - Pavilion R (in the lobby) 900 St-Denis St. Montreal, Québec H2X 0A9

SOURCE TVM Capital

Media Contact: Marie-Christine Garon, Cabinet de relations publiques NATIONAL, 514-409-0031, [email protected]; Alex-Sandra Thibault, Cabinet de relations publiques NATIONAL, 514-843-2375, [email protected]